Cambridge-based PetMedix reveals that its first-ever fully canine monoclonal antibodies were used successfully in a canine trial, outperforming all relevant benchmarks.
The PetMedix team discovered these antibodies using the unique proprietary Ky9™ transgenic platform and conducted this first-of-its-kind study as part of an internal discovery campaign.
The advance positions PetMedix to lead the next generation of therapeutic antibody development in animal health, matching leading-edge human technology with unmet pet health needs.
“This is a huge milestone for the company, one of which every single person working at the company should be proud,” says PetMedix CEO Tom Weaver.
“To be the first company ever to develop a fully canine therapeutic antibody, and to find out that it supports dog health and welfare – not just well but better than anything else out there – is an incredible achievement. That the team that pulled this off has only been around for 2.5 years only makes it more impressive.”
Monoclonal antibodies first garnered significant attention in the animal…
